Skip to content
DelNova: Addressing complications from Botox (217) episode artwork

May 24, 2022 19 min

DelNova: Addressing complications from Botox (217)

from Innovation4Alpha Hosted by Innovation4Alpha

DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

DelNova: Addressing complications from Botox (217)

0:00 19:03

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Innovation4Alpha?

This episode is 19 minutes long.

When was this Innovation4Alpha episode published?

This episode was published on May 24, 2022.

Can I download this Innovation4Alpha episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.